What is good about PD + HD combined therapy.

Area of Science:

• Nephrology
• Renal Replacement Therapy
• Biomedical Engineering

Background:

• Beta-2 microglobulin (β(2)-MG) concentration correlates inversely with residual renal function (RRF) in peritoneal dialysis (PD) patients.
• Declining RRF in PD patients may necessitate the addition of hemodialysis (HD) for effective solute and fluid removal.
• Combined PD and HD therapy is explored for long-term PD patients to manage larger solutes like β(2)-MG.

Purpose of the Study:

• To evaluate the benefits of a combined 5-day PD + 1-day HD per week therapy in long-term PD patients using a kinetic model.
• To assess the impact of different dialyzer types on solute clearance, particularly β(2)-MG, within the combined therapy regimen.

Main Methods:

• A mathematical kinetic model based on compartment theory was developed and validated with clinical data.
• The model simulated the effects of combined PD + HD therapy (5-day PD + 1-HD/week) on solute concentrations.
• Simulations compared the use of low-flux versus super high-flux dialyzers for β(2)-MG clearance.

Main Results:

• Combined PD + HD therapy reduced time-averaged concentrations (TAC) of urea and creatinine by approximately 20%, irrespective of dialyzer type.
• TAC for β(2)-MG was highly dependent on dialyzer clearance; low-flux dialyzers could lead to increased pre-dialysis β(2)-MG levels.
• Super high-flux dialyzers significantly reduced β(2)-MG from 30 mg/L to 8 mg/L within a 4-hour HD treatment.

Conclusions:

• Combined PD + HD therapy is beneficial for PD patients with diminishing RRF.
• The use of super high-flux dialyzers is critical in combined therapy to prevent the accumulation of β(2)-MG and other large solutes.
• Super high-flux dialyzers are key to the success of PD + HD combined therapy, ensuring effective clearance of larger molecules.